Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Atsushi TanakaShigeru ToyodaTakumi ImaiKazuki ShiinaHirofumi TomiyamaYasushi MatsuzawaTakahiro OkumuraYumiko KanzakiKatsuya OnishiArihiro KiyosueMasami NishinoYasushi SakataKoichi Nodenull nullPublished in: Cardiovascular diabetology (2021)
The impact of canagliflozin treatment on NT-proBNP concentration appears to be independent of the background use of diabetes therapy in the patient population examined. Trial registration University Medical Information Network Clinical Trial Registry, number 000017669. Registered on May 25, 2015.
Keyphrases
- clinical trial
- phase ii
- study protocol
- phase iii
- type diabetes
- healthcare
- case report
- open label
- white matter
- resting state
- ejection fraction
- metabolic syndrome
- randomized controlled trial
- anti inflammatory
- multiple sclerosis
- combination therapy
- blood brain barrier
- cerebral ischemia
- social media
- skeletal muscle
- subarachnoid hemorrhage
- smoking cessation
- network analysis